IDEAYA And AstraZeneca Collaboration Adds New Dimension To IDE849 And Valuation

Simply Wall St.10:13

IDEAYA Biosciences (NasdaqGS:IDYA) has entered a clinical collaboration with AstraZeneca to study IDE849, a DLL3 TOP1 antibody drug conjugate. The program will evaluate IDE849 in combination with ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629053098?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-22 10:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629053098","market":"us","top_or_hot":-1,"title":"IDEAYA And AstraZeneca Collaboration Adds New Dimension To IDE849 And Valuation","media":"Simply Wall St.","content":"<div>\n<p>IDEAYA Biosciences (NasdaqGS:IDYA) has entered a clinical collaboration with AstraZeneca to study IDE849, a DLL3 TOP1 antibody drug conjugate. The program will evaluate IDE849 in combination with ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-idya/ideaya-biosciences/news/ideaya-and-astrazeneca-collaboration-adds-new-dimension-to-i\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IDEAYA And AstraZeneca Collaboration Adds New Dimension To IDE849 And Valuation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIDEAYA And AstraZeneca Collaboration Adds New Dimension To IDE849 And Valuation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-22 10:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-idya/ideaya-biosciences/news/ideaya-and-astrazeneca-collaboration-adds-new-dimension-to-i><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>IDEAYA Biosciences (NasdaqGS:IDYA) has entered a clinical collaboration with AstraZeneca to study IDE849, a DLL3 TOP1 antibody drug conjugate. The program will evaluate IDE849 in combination with ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-idya/ideaya-biosciences/news/ideaya-and-astrazeneca-collaboration-adds-new-dimension-to-i\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-idya/ideaya-biosciences/news/ideaya-and-astrazeneca-collaboration-adds-new-dimension-to-i","article_id":"2629053098","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-idya/ideaya-biosciences/news/ideaya-and-astrazeneca-collaboration-adds-new-dimension-to-i","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2629053098","pubTimestamp":1776823987,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"IDEAYA Biosciences (NasdaqGS:IDYA) has entered a clinical collaboration with AstraZeneca to study IDE849, a DLL3 TOP1 antibody drug conjugate.\nThe program will evaluate IDE849 in combination with Imfinzi in extensive stage small cell lung cancer and other DLL3 upregulated tumors.\n\nFor readers tracking IDEAYA mainly through its uveal melanoma drug darovasertib, this collaboration with AstraZeneca broadens the story. The company, trading at $31.83, has delivered a 70.9% return over the past...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IDYA":"IDEAYA Biosciences"},"translate_title":"IDEAYA和阿斯利康的合作为IDE849和估值增添了新的维度","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDYA":0.9},"content_text":"IDEAYA Biosciences (NasdaqGS:IDYA) has entered a clinical collaboration with AstraZeneca to study IDE849, a DLL3 TOP1 antibody drug conjugate. The program will evaluate IDE849 in combination with Imfinzi in extensive stage small cell lung cancer and other DLL3 upregulated tumors.  For readers tracking IDEAYA mainly through its uveal melanoma drug darovasertib, this collaboration with AstraZeneca broadens the story. The company, trading at $31.83, has delivered a 70.9% return over the past year and 70.8% over three years, which indicates increased market attention to its oncology pipeline. The new IDE849 program adds a different angle in difficult to treat tumor types such as small cell lung cancer and neuroendocrine tumors. Partnering with a large pharmaceutical group on IDE849 gives IDEAYA access to additional clinical and development expertise in immuno oncology. For investors, the key points to monitor will be trial design, early safety and activity signals, and any future updates on how this DLL3 program fits alongside the rest of IDEAYA's pipeline. Stay updated on the most important news stories for IDEAYA Biosciences by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on IDEAYA Biosciences. NasdaqGS:IDYA Earnings & Revenue Growth as at Apr 2026 We've flagged 1 risk for IDEAYA Biosciences. See which could impact your investment. AdvertisementQuick Assessment  ✅ Price vs Analyst Target: At US$31.83, the price sits roughly 40% below the US$52.81 analyst target. ✅ Simply Wall St Valuation: Shares are flagged as trading about 88.4% below the platform's estimated fair value. ❌ Recent Momentum: The 30 day return of about 2.8% decline shows weak short term sentiment despite the news.  There is only one way to know the right time to buy, sell or hold IDEAYA Biosciences. Head to the Simply Wall St\ncompany report for the latest analysis of IDEAYA Biosciences's Fair Value. Key Considerations  📊 The AstraZeneca collaboration puts external validation on IDE849, which may strengthen the overall investment case around IDEAYA's oncology focus. 📊 Watch upcoming IDE849 trial updates, revenue trends and any changes to fair value estimates relative to the current US$31.83 share price. ⚠️ IDEAYA is currently loss making and is not expected to reach profitability within the next 3 years, so progress on funding and pipeline milestones is crucial.  Dig Deeper For the full picture including more risks and rewards, check out the\ncomplete IDEAYA Biosciences analysis. Alternatively, you can visit the\ncommunity page for IDEAYA Biosciences to see how other investors believe this latest news will impact the company's narrative.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629053098","isCrawlerRequest":true}